An artificial short peptide, composition, and its antihypertensive application for intervening in abnormal palmitoylation of GRK4
By designing a peptide EVTCGL with a specific amino acid sequence to bind to TAT cell membrane-penetrating peptide and using PLGA-PEG nanocarriers to achieve kidney-targeted delivery, the problem of insufficient specific intervention of existing drugs on abnormal palmitoylation of GRK4 is solved, significantly reducing GRK4 protein expression and blood pressure, and providing effective treatment for hypertension.
Patent Information
- Application Number
- CN202611472484.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-21
- Publication Date
- 2026-11-17
AI Technical Summary
Existing antihypertensive drugs lack specific intervention for abnormal palmitoylation of GRK4 in obese individuals, and conventional peptides have insufficient stability in vivo and renal targeting, resulting in poor treatment efficacy.
A peptide composition comprising a specific amino acid sequence short peptide EVTCGL is designed, which is combined with the cell-penetrating peptide TAT to form TAT-EVTCGL, and then delivered to the kidney via a PLGA-PEG nanocarrier delivery system using a proximal renal tubule-targeting peptide to achieve renal targeted delivery, thus preparing a targeted drug delivery system.
It significantly reduces GRK4 protein expression and S-palmitoylation levels, reduces hypertension, especially obesity-related hypertension, and provides specific interventions and kidney-targeted therapies for GRK4 abnormalities.
Smart Images

Figure CN123106829A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, and in particular relates to an artificial short peptide, composition and its antihypertensive application for intervening in abnormal palmitoylation of GRK4. Background Technology
[0002] Hypertension is a significant risk factor for adverse cardiovascular events and end-stage renal disease. Obesity, as a major contributing factor to essential hypertension, can cause ectopic lipid deposition in the kidneys, leading to enhanced sodium reabsorption in the proximal tubules and impaired urinary sodium excretion, thereby promoting sustained hypertension. G protein-coupled receptor kinase 4 (GRK4) plays an important role in renal receptor regulation and blood pressure homeostasis. In obese individuals, renal tubular GRK4 protein expression is elevated, accompanied by enhanced S-palmitoylation modification; this lipid modification can affect GRK4 stability and intracellular accumulation, thereby interfering with renal sodium excretion-related signaling.
[0003] Current conventional antihypertensive drugs mainly act on pathways such as the sympathetic nervous system, diuresis, or calcium channels, lacking specific intervention for the pathological processes related to GRK4 abnormalities in obese individuals. Non-specific palmitoylation inhibitors may simultaneously affect multiple normally functional proteins; the clinical translation pathways of gene knockout or viral vector methods are complex. On the other hand, free peptides are easily cleaved by enzymes, resulting in problems such as short in vivo half-life, low tissue localization efficiency, and difficulty in maintaining effective concentrations. Therefore, it is necessary to develop peptide formulations that can specifically intervene in abnormal GRK4 palmitoylation and whose in vivo stability and renal targeting can be improved with the help of suitable delivery systems. Summary of the Invention
[0004] To address the shortcomings of existing technologies, this invention proposes an artificial short peptide, composition, and its antihypertensive application for intervening in abnormal palmitoylation of GRK4.
[0005] The technical solution of this invention is as follows: A polypeptide, the amino acid sequence of which is shown in SEQ ID NO:1.
[0006] Furthermore, the polypeptide is a pharmaceutically acceptable salt of itself; or, the N-terminus or C-terminus of the polypeptide is chemically modified, the chemical modification being selected from at least one of acetylation, amidation, PEGylation, or fluorescent labeling.
[0007] A fusion polypeptide comprising the polypeptide shown in SEQ ID NO:1 and a cell-penetrating peptide attached to the N-terminus of the polypeptide.
[0008] Furthermore, the amino acid sequence of the cell-penetrating peptide is shown in SEQ ID NO:2, and the amino acid sequence of the fusion polypeptide is shown in SEQ ID NO:3.
[0009] A targeted drug delivery system includes a nanocarrier and an active ingredient loaded in the nanocarrier; the active ingredient is a polypeptide shown in SEQ ID NO:1 or a fusion polypeptide shown in SEQ ID NO:3; a kidney-targeting peptide is attached to the surface of the nanocarrier.
[0010] Furthermore, the nanocarrier is PLGA-PEG nanoparticles; the kidney-targeting peptide is a proximal renal tubule-targeting peptide, and its amino acid sequence is shown in SEQ ID NO:4.
[0011] The application of the polypeptide shown in SEQ ID NO:1, the fusion polypeptide shown in SEQ ID NO:3, or the targeted drug delivery system in the preparation of antihypertensive drugs.
[0012] Furthermore, the antihypertensive drug is a drug for treating obesity-related hypertension, salt-sensitive hypertension, or renal hypertension.
[0013] The use of the polypeptide shown in SEQ ID NO:1, the fusion polypeptide shown in SEQ ID NO:3, or the targeted drug delivery system described herein in the preparation of drugs that inhibit GRK4 protein expression or intervene in GRK4 protein palmitoylation modification.
[0014] Compared with the prior art, the present invention has the following advantages: 1. This invention provides a short peptide EVTCGL composed of 6 amino acids, with the amino acid sequence shown in SEQ ID NO:1. When linked with the TAT cell-penetrating peptide to form TAT-EVTCGL, it can be used for cellular-level intervention. HK-2 cell experiments showed that TAT-EVTCGL significantly reduced the relative expression of GRK4 protein at 25 μM and 50 μM conditions, and 25 μM TAT-EVTCGL also significantly reduced GRK4 S-palmitoylation levels.
[0015] 2. This invention further provides a PLGA-PEG nanoformulation modified with KTP and loaded with EVTCGL. Animal experiments show that this formulation can reduce the level of GRK4 protein and S-palmitoylation in the renal cortex of obesity-related hypertensive mice induced by a high-fat diet, and reduce systolic and diastolic blood pressure, providing a new technical solution for targeted intervention against pathological links related to GRK4 abnormalities. Attached Figure Description
[0016] To more clearly illustrate the specific embodiments of the present invention, the accompanying drawings used in the specific embodiments are briefly described below.
[0017] Figure 1 The HPLC identification chromatogram (Chromatogram; min; uV) of the synthesized TAT-EVTCGL in Example 1 is shown.
[0018] Figure 2 The image shows the LC-MS identification spectrum (MS Spectrum: mass spectrum; Intensity: intensity; m / z: mass-to-charge ratio) of the TAT-EVTCGL synthesized in Example 1.
[0019] Figure 3 The graph shows the changes in GRK4 protein expression and S-palmitoylation levels after 48 hours of TAT-EVTCGL treatment of HK-2 cells in Example 2. A is a representative Western blot of GRK4 and internal control GAPDH after treatment with different concentrations of TAT-EVTCGL; B is a quantitative statistical graph of the relative expression level of GRK4 protein; C is a representative graph of GRK4 S-palmitoylation detected by acyl-biotin exchange method after treatment with TAT-only and 25 μM TAT-EVTCGL, where +HAM / -HAM was set and total GRK4 in the input was detected; D is a quantitative statistical graph of Palm-GRK4 / total GRK4 in the input (kDa: kilodaltons; μM: micromoles per liter; WB: Western blotting; ***p < 0.001, ****p < 0.0001). Figure 3 The "-" in A and B indicates TAT-only normalized reference.
[0020] Figure 4 The graph shows the changes in GRK4 protein expression and S-palmitoylation levels in the renal cortex of obesity-related hypertensive mice after treatment with EVTCGL nanoparticles in Example 3. A is a representative Western blot of renal cortical GRK4 and internal control GAPDH; B is a quantitative statistical graph of the relative expression of GRK4 protein; C is a representative graph of renal cortical GRK4 S-palmitoylation detected by acyl-biotin exchange method combined with GRK4 immunoprecipitation, with +HAM / -HAM settings; the top row shows the Streptavidin-IRDye 800CW detection results of GRK4 immunoprecipitation products, and the bottom row shows the Western blot results of the corresponding Input total GRK4; D is a quantitative statistical graph of Palm-GRK4 / Input total GRK4 (Blank-NPs: empty nanoparticle group; EVTCGL-NPs: EVTCGL nanoparticle group; **p < 0.01, ****p < 0.0001).
[0021] Figure 5This is a plot comparing the intergroup endpoints of systolic and diastolic blood pressure in obesity-related hypertensive mice treated with the EVTCGL nanoparticles in Example 3 (SBP: systolic blood pressure; DBP: diastolic blood pressure; mmHg: millimeters of mercury; *p < 0.05). Note: Blood pressure data for the Blank-NPs group were obtained from a common empty control group (n=6) set up in the same batch of parallel experiments with multiple materials. Detailed Implementation
[0022] The present invention will now be described in further detail. The specific embodiments described below are for illustrative purposes only and should not be construed as limiting the scope of protection of the present invention. Those skilled in the art can make improvements and adjustments based on the disclosure of this application without departing from the essence of the present invention.
[0023] This invention provides a general and / or specific description of the materials and experimental methods used in the experiments. Unless otherwise specified, all experimental or testing methods are conventional methods; reagents or instruments used, unless otherwise specified, are commercially available conventional products prepared or used using conventional methods.
[0024] Unless otherwise defined, the technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art.
[0025] Example 1: Solid-phase synthesis and physicochemical identification of polypeptides Sequence Design: The core short peptide EVTCGL of this invention consists of 6 amino acids, and its amino acid sequence is shown in SEQ ID NO:1. To improve cellular uptake efficiency, TAT cell-penetrating peptide (SEQ ID NO:2) was linked to the N-terminus of EVTCGL to obtain the fusion polypeptide TAT-EVTCGL, the full-length amino acid sequence of which is shown in SEQ ID NO:3. TAT-only was used as an equimolar control in cell experiments.
[0026] Synthesis and Detection: Both TAT-EVTCGL and TAT-only were prepared by Sangon Biotech (Shanghai) Co., Ltd. using commercial solid-phase peptide synthesis technology. The purity of the synthesized products was detected by high performance liquid chromatography (HPLC), and the molecular weight was detected by liquid chromatography-mass spectrometry (LC-MS).
[0027] HPLC results: such as Figure 1As shown, the TAT-EVTCGL was chromatographically performed using a SHIMADZU shim-pack GIST C18 column (4.6 × 250 mm, 5 μm). Mobile phase A was an aqueous solution containing 0.1% trifluoroacetic acid, and mobile phase B was an acetonitrile solution containing 0.1% trifluoroacetic acid. The flow rate was 1.0 mL / min, the detection wavelength was 214 nm, and the injection volume was 30 μL. 0.5 mg of sample was dissolved in 0.5 mL of water, and phase B was gradient-increased from 16% to 36%. The retention time of the main peak was 13.110 min, and the percentage of the main peak area was 95.040%.
[0028] LC-MS results: such as Figure 2 As shown, the theoretical relative molecular mass of TAT-EVTCGL is 2162.538, while the measured value is 2162.50. The measured result is consistent with the theoretical value, indicating that the obtained synthetic product is the target polypeptide.
[0029] Example 2: TAT-EVTCGL reduces GRK4 protein expression and S-palmitoylation levels in HK-2 cells. Experimental materials: human renal cortical proximal tubule epithelial cells (HK-2 cells), TAT-EVTCGL, TAT-only, GRK4 antibody, GAPDH internal control antibody, and Western blot related reagents; palmitoylation detection was performed using N-ethylmaleimide, hydroxylamine (HAM), biotin-HPDP, and streptavidin magnetic beads.
[0030] GRK4 protein expression assay: HK-2 cells were cultured to a suitable density under standard conditions. Three concentrations of TAT-EVTCGL were set: 10 μM, 25 μM, and 50 μM. For each concentration, a TAT-only control with the same molar concentration was included. The treatment time was 48 hours. All TAT-only controls were completed, and the results were comparable to the solvent reference. To avoid duplication, the results for each TAT-only dose are not shown individually in the figures; instead, they are represented by the normalized TAT-only reference value. Each group was independently replicated (n=4). After treatment, total protein was extracted, and GRK4 and GAPDH were detected by Western blot. The GRK4 / GAPDH ratio was used as the quantitative indicator. The attached figures show representative bands of GRK4 and GAPDH. Quantification was performed according to the GRK4 / GAPDH ratio. Ordinary one-way ANOVA and Dunnett multiple comparisons were performed.
[0031] Experimental results: such as Figure 3 A, Figure 3As shown in B and Table 1, the relative expression level of GRK4 protein in the TAT-only group was 1.000 ± 0.000; the relative expression levels in the 10 μM, 25 μM, and 50 μM TAT-EVTCGL groups were 0.985 ± 0.048, 0.293 ± 0.055, and 0.240 ± 0.045, respectively. One-way ANOVA showed that the overall differences between groups were statistically significant (F = 94.902, p = 1.26 × 10⁻⁶). -8 Compared with TAT-only, there was no statistically significant difference in the 10 μM group (p=0.989), while the 25 μM and 50 μM groups were significantly reduced (both p<0.0001).
[0032] Table 1. Relative expression levels of GRK4 protein in HK-2 cells after TAT-EVTCGL treatment.
[0033] GRK4 S-palmitoylation assay: Two groups were set up: a TAT-only group and a 25 μM TAT-EVTCGL group. Both groups were treated for 48 hours, with independent replicates (n=4) for each group. GRK4 S-palmitoylation was detected using the acyl-biotin exchange (ABE) method: Free thiol groups were blocked with N-ethylmaleimide, and an equal amount of sample was retained as input. The remaining samples were divided into +HAM and -HAM groups. Newly exposed thiol groups were then labeled with biotin-HPDP, and biotinylated proteins were enriched using streptavidin magnetic beads. After washing, SDS-PAGE and Western blot were performed to detect GRK4. The ratio of Palm-GRK4 to the total GRK4 in the corresponding input under the +HAM condition was used as the quantitative indicator and normalized to the TAT-only group. Western blot bands are shown as representative images.
[0034] Experimental results: such as Figure 3 C Figure 3 As shown in Table 2, the relative level of GRK4 S-palmitoylation in the TAT-only group was 1.000 ± 0.000; in the 25 μM TAT-EVTCGL group, it decreased to 0.448 ± 0.041. A Welch-corrected two-independent-samples t-test showed that the difference between the two groups was statistically significant (p = 0.000877). The results indicate that TAT-EVTCGL can reduce the level of GRK4 S-palmitoylation in HK-2 cells.
[0035] Table 2. GRK4 S-palmitoylation level in HK-2 cells after TAT-EVTCGL treatment.
[0036] Example 3: Preparation, characterization, and animal experiment validation of EVTCGL nanoformulation. Preparation of EVTCGL nanoparticles: The active polypeptide used in animal experiments was EVTCGL (SEQ ID NO:1), without the TAT cell-penetrating peptide. The carrier material used was PLGA-PEG modified with the proximal renal tubule targeting peptide KTP (SEQ ID NO:4) (PEG chain molecular weight 5000, Xi'an Ruixi Biotechnology Co., Ltd., catalog number 20250324-DT1). KTP-modified PLGA-PEG was dissolved in 2.4 mL of dichloromethane to form an organic phase; EVTCGL was dissolved in deionized water to form an aqueous phase. The organic phase was slowly added to the aqueous phase containing EVTCGL, and the mixture was ultrasonically emulsified for 10 min, followed by stirring for 1 h to remove dichloromethane. Unloaded free polypeptides were removed by dialysis, and the nanoparticle dispersion was brought to a final volume of 5 mL. After adding a lyophilization protectant, the mixture was freeze-dried to obtain EVTCGL-NPs. Blank-NPs were prepared using the same process but without the addition of EVTCGL.
[0037] Nanoparticle characterization: Particle size, PDI, and Zeta potential are all results from three measurements and are expressed as mean ± SD. The average particle size of Blank-NPs was 141.88 ± 9.03 nm, PDI was 0.142 ± 0.015, and Zeta potential was -20.69 ± 1.36 mV; the average particle size of EVTCGL-NPs was 153.35 ± 5.17 nm, PDI was 0.159 ± 0.016, and Zeta potential was -18.52 ± 1.65 mV. The drug loading of EVTCGL-NPs was 4.5%, and the encapsulation efficiency was 75%. Drug loading was calculated as the mass of loaded EVTCGLs / the mass of the carrier × 100%, and encapsulation efficiency was calculated as the mass of loaded EVTCGLs / the total mass of EVTCGLs added × 100%. The results are shown in Table 3.
[0038] Table 3 Physicochemical characterization of EVTCGL nanoformulation (mean ± SD, n=3)
[0039] Experimental animals and models: Eight-week-old male C57BL / 6J mice weighing 22–25 g were used. After acclimatization, they were fed a high-fat diet with 60% fat as an energy source for 16 consecutive weeks to establish an obesity-related hypertension model. Animals had free access to water and food, and were fed and handled according to standard laboratory animal management practices during the experiment.
[0040] Dosing Groups: This animal experiment evaluated multiple test materials in parallel within the same batch. Model mice were randomly assigned to the Blank-NPs empty-load control group and each test material group. This example reports the Blank-NPs group (empty-load nanoparticle group) and the EVTCGL-NPs group (EVTCGL nanoparticle formulation group). The Blank-NPs group for blood pressure evaluation served as a shared control group for all test materials in the same batch, comprising 6 animals. Administration was via tail vein injection. The EVTCGL-NPs group received a dose of 2 mg / kg based on EVTCGL, while the Blank-NPs group received an equal volume of empty-load nanoparticles. Dosing was administered every other day for 7 consecutive days. Blood pressure was measured in n=6 per group, and renal cortex measurements were performed in n=4 per group.
[0041] Detection and Statistics: After the course of drug administration, systolic blood pressure (SBP) and diastolic blood pressure (DBP) of mice were measured using the non-invasive tail-cloak method. Subsequently, renal cortical tissue was collected, and GRK4 and GAPDH were detected by Western blot. The relative expression level of GRK4 protein was expressed as the GRK4 / GAPDH ratio. The attached figure shows representative bands of GRK4 and GAPDH. Quantification was performed according to the GRK4 / GAPDH ratio described above. GRK4 S-palmitoylation was detected using the acyl-biotin exchange assay (ABE) combined with GRK4 immunoprecipitation. A hydroxylamine-treated group (+HAM) and a negative control group without hydroxylamine (-HAM) were set up. The biotinylated signal in the GRK4 immunoprecipitation product was detected using a Streptavidin-IRDye 800CW instrument. Total GRK4 in the corresponding input sample was detected by Western blot. Quantification was performed using the ratio of Palm-GRK4 signal under +HAM conditions to the corresponding total GRK4 signal in the input sample. An unpaired t-test was used between the two groups.
[0042] Renal cortical GRK4 protein expression: such as Figure 4 A, Figure 4 As shown in B and Table 4, the relative expression level of GRK4 protein in the Blank-NPs group was 0.978 ± 0.103, while that in the EVTCGL-NPs group was 0.348 ± 0.065; the EVTCGL-NPs group was significantly lower than that in the Blank-NPs group (p=0.00205).
[0043] Renal cortical GRK4 S-palmitoylation: such as Figure 4 C Figure 4 As shown in Table D and Table 4, the relative level of GRK4 S-palmitoylation in the Blank-NPs group was 1.000 ± 0.000, while that in the EVTCGL-NPs group was 0.198 ± 0.083; the EVTCGL-NPs group was significantly lower than that in the Blank-NPs group (p<0.0001).
[0044] Blood pressure endpoint: such as Figure 5 As shown in Table 4, the systolic blood pressure of mice in the Blank-NPs group was 126.37 ± 3.25 mmHg, and that in the EVTCGL-NPs group was 110.25 ± 4.56 mmHg (p=0.0164); the diastolic blood pressure of the Blank-NPs group was 87.50 ± 3.84 mmHg, and that in the EVTCGL-NPs group was 72.00 ± 3.82 mmHg (p=0.0169). These results represent inter-group endpoint comparisons after the drug administration was completed, indicating that EVTCGL-NPs can reduce both systolic and diastolic blood pressure in obesity-related hypertensive mice.
[0045] Table 4. Comparison of endpoint indicators in obesity-related hypertensive mice after treatment with EVTCGL nanoformulation.
[0046] Note: Blood pressure data for the Blank-NPs group were obtained from a common unloaded control group (n=6) set up in the same batch of parallel experiments with multiple materials.
[0047] The above results indicate that EVTCGL delivered via KTP-modified PLGA-PEG nanoparticles can reduce GRK4 protein expression and S-palmitoylation levels in the renal cortex of obesity-associated hypertensive mice, and decrease systolic and diastolic blood pressure.
[0048] The sequence involved in this invention is as follows.
[0049] SEQ ID NO:1 EVTCGL.
[0050] SEQ ID NO:2 YGRKKRRQRRR.
[0051] SEQ ID NO:3 YGRKKRRQRRREVTCGL.
[0052] SEQ ID NO:4 KKEEEKKEEEKKEEEK.
[0053] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit them. Those skilled in the art can modify the technical solutions described in the foregoing embodiments, or make equivalent substitutions for some or all of the technical features therein; these modifications or substitutions do not cause the substance of the corresponding technical solutions to depart from the scope defined by the claims and specification of the present invention.
Claims
1. A polypeptide, characterized in that, The amino acid sequence of the polypeptide is shown in SEQ ID NO:
1.
2. The polypeptide according to claim 1, characterized in that, The polypeptide is a pharmaceutically acceptable salt of itself; or, the N-terminus or C-terminus of the polypeptide is chemically modified, the chemical modification being selected from at least one of acetylation, amidation, PEGylation, or fluorescent labeling.
3. A fusion polypeptide, characterized in that, The fusion polypeptide includes the polypeptide shown in SEQ ID NO:1 and a cell-penetrating peptide linked to the N-terminus of the polypeptide.
4. The fusion polypeptide according to claim 3, characterized in that, The amino acid sequence of the cell-penetrating peptide is shown in SEQ ID NO:2, and the amino acid sequence of the fusion polypeptide is shown in SEQ ID NO:
3.
5. A targeted drug delivery system, characterized in that, It includes a nanocarrier and an active ingredient loaded in the nanocarrier; the active ingredient is the polypeptide of claim 1 or 2, or the fusion polypeptide of claim 3 or 4; the surface of the nanocarrier is attached with a kidney-targeting peptide.
6. The targeted drug delivery system according to claim 5, characterized in that, The nanocarrier is PLGA-PEG nanoparticles; the kidney-targeting peptide is a proximal renal tubule-targeting peptide, and the amino acid sequence of the proximal renal tubule-targeting peptide is shown in SEQ ID NO:
4.
7. The use of the polypeptide of claim 1 or 2, the fusion polypeptide of claim 3 or 4, or the targeted drug delivery system of claim 5 or 6 in the preparation of antihypertensive drugs.
8. The application according to claim 7, characterized in that, The antihypertensive drugs mentioned are those used to treat obesity-related hypertension, salt-sensitive hypertension, or renal hypertension.
9. The use of the polypeptide of claim 1 or 2, the fusion polypeptide of claim 3 or 4, or the targeted drug delivery system of claim 5 or 6 in the preparation of a drug that inhibits GRK4 protein expression or intervenes in GRK4 protein palmitoylation modification.
